Clinical Trials Logo

Aortic Valve Disease clinical trials

View clinical trials related to Aortic Valve Disease.

Filter by:

NCT ID: NCT05932615 Recruiting - Clinical trials for Aortic Valve Stenosis

ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

ENVISION
Start date: March 19, 2024
Phase: N/A
Study type: Interventional

The objective of ENVISION is to evaluate the safety and effectiveness of the Navitor Transcatheter Aortic Valve Implantation (TAVI) System for treating patients with symptomatic, severe native aortic stenosis who are considered intermediate or low risk for surgical mortality.

NCT ID: NCT05806411 Recruiting - Clinical trials for Calcific Aortic Valve Diasease

Calcific Aortic Valve Disease:the Role of Bacteria as Trigger of a Chronic Inflammation

Start date: January 18, 2023
Phase:
Study type: Observational

Calcific aoric valve disease (CAVD) is extremely common worldwide, affecting almost 50% of the population over 85 years of age, with a lethality higher than 50% at 2 years for symptomatic patients, unless aortic-valve replacement is performed. CAVD is characterized by slowly progressive fibro-calcific remodelling of the valve leaflets causing aortic stenosis. The spectrum of the disease progression starts with leaflet degeneration and progresses from early lesions to valve stenosis/obstruction, which is initially mild to moderate but eventually becomes severe. Risk factors for CAVD partly overlap those for atherosclerosis but also intake age-related tissue changes and effects of comorbiditiies (e.g. renal failure) in the overall complex mechanisms of valve leaflet degeneration, which is, at present, unpreventable, leaving aortic valve repair the only treatment option for severe aortic stenosis. In the first phase of the disease the valve becomes thickened and mildly calcified, then the disease evolves to severe valve calcification with impaired leaflet motion and vast blood flow obstruction. Calcific AS valves show advanced osteogenic metaplasia with the presence of osteoblast-like cells and chondrocytes associated with dense inflammatory infiltrates. Bacteria have been detected in the absence of diagnosis of acute infective endocarditis, but their role is still unknown. Different bacterial species (C. acnes (59%), E. faecalis (16%), S. aureus (15%), and S. pyogenes (10%)) have been typed and intramural bacterial colonization has been observed in patients with calcified structural valvular heart disease. Indeed, it has been recently demonstrated that bacterial infections can directly affect osteoblast differentiation/activation. The Authors hypothesized that a subclinical or latent valvular bacterial infiltration facilitates a chronic inflammation and contributes to accelerated structural valve degeneration. An interdisciplinary team has been established to investigate the infective, biochemical and structural features of calcific aortic valve disease.

NCT ID: NCT05758909 Recruiting - Clinical trials for Aortic Valve Stenosis

Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation

FAST TRACK
Start date: April 4, 2023
Phase:
Study type: Observational [Patient Registry]

Evaluation of the safety and efficacy of early discharge (24 hours) after transfemoral transcatheter aortic prosthesis implantation (TAVI).

NCT ID: NCT05670041 Recruiting - Clinical trials for Aortic Valve Stenosis

Re-hospitalisation After Transcatheter Aortic Valve Implantation

HOSPITAVI
Start date: January 16, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to investigate whether patient-tailored follow-up for patients treated with transcatheter aortic valve implantation (TAVI) can prevent re-hospitalisation and improve quality of life compared with the standard follow-up program. The rationale of this study is the persistently high rate of re-hospitalisation after TAVI, which increases the risk of mortality and diminishes the patient-evaluated quality of life. Our hypothesis is that patient-tailored follow-up for patients treated with TAVI will reduce the rate of re-hospitalisation after the TAVI-procedure and improve quality of life. The primary endpoints are the rate of re-hospitalisation within 90 days of the procedure and quality of life adjusted life years at 90-day follow-up.

NCT ID: NCT05656820 Recruiting - Clinical trials for Bicuspid Aortic Valve Disease

Bicuspid Echocardiac Study Team(BEST)

BEST
Start date: July 1, 2022
Phase:
Study type: Observational

The Chinese Bicuspid Aortic Valve (BAV) Ultrasound imaging cohort study is a Chinese BAV ultrasound imaging cohort study. At present, a retrospective study cohort involving more than 30 hospitals has been established. The prospective multi-center study of BAV is expected to include and follow up 200 outpatients and inpatients with BAV. The clinical, ultrasound imaging and treatment parameters of the patients are collected and the patients are followed up for 2 years. To analyze the prognostic characteristics of BAV patients and establish a Chinese BAV database. The primary endpoint was all-cause death, and the secondary endpoints were heart failure, angina, severe aortic stenosis, severe aortic insufficiency, ascending aortic diameter ≥50mm, and surgery (surgical and interventional). According to the different pathological types of aortic valve in different types of BAV, ultrasound imaging was used to evaluate the different forms of valvular leaflet lesions and prognosis. Finally, it provides a basis for the prognosis, treatment method, treatment timing and treatment plan selection of BAV patients, and lays a foundation for the mechanism study of BAV arterial lesions and the establishment of risk model for the prognosis of BAV patients.

NCT ID: NCT05635227 Recruiting - Clinical trials for Coronary Artery Disease

Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery

GLORIOUS-II
Start date: November 10, 2022
Phase: N/A
Study type: Interventional

Open heart surgery, including coronary artery bypass grafting (CABG) and/or aortic valve replacement (AVR) is associated with a significant risk of mortality. This study is a randomized clinical trial with the purpose of investigating four different interventions on the primary endpoint 'days alive and outside of hospital within 90 days'. The interventions are: - Dexamethasone vs. placebo administered after induction of anesthesia. - Olanzapine vs. placebo administered prior to anesthesia. - A blood-flow targeted vs. a blod-pressure targeted hemodynamic strategy while the patient is on cardio-pulmonary bypass (CPB) - Low-tidal volume ventilation vs. no ventilation of the lungs while the patient is on CPB

NCT ID: NCT05620875 Recruiting - Clinical trials for Aortic Valve Disease

The Association Between Delivered Oxygen and Cerebral Impact During the Use of Cardiopulmonary Bypass.

Start date: January 2, 2023
Phase:
Study type: Observational [Patient Registry]

Investigating the connection between delivered oxygen index and cerebral impact with COx (cerebral oximetry index) och cerebral injury markers during the routine use of cardiopulmonary bypass.

NCT ID: NCT05607667 Recruiting - Clinical trials for Diseases of Aortic Valve

Clinical Trial in China for Aortic Valve Stenosis

Start date: October 27, 2022
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to evaluate the effectiveness and safety of the transcatheter aortic valve system in the treatment of patients with severe aortic stenosis disease who are at high or prohibitive surgical risk.

NCT ID: NCT05580952 Recruiting - Clinical trials for Diseases of Aortic Valve

Clinical Trial in China

Start date: October 14, 2022
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to evaluate the effectiveness and safety of the transcatheter aortic valve system in the treatment of patients with severe aortic regurgitation disease who are at high or prohibitive surgical risk.

NCT ID: NCT05484713 Recruiting - Aortic Stenosis Clinical Trials

Feasibility of 3D Printed Models of Aortic Stenosis in Guiding TAVI Procedure

3DP-FAST
Start date: July 8, 2022
Phase:
Study type: Observational

• The aim of 3DP-FAST study is to analyze the accuracy of replicating cardiovascular anatomical structures using different techniques and to evaluate the feasibility of 3D printed models of aortic stenosis in guiding TAVI procedure. By conducting a comparative analysis of measurements achieved on CCTA images versus measurements obtained with a specialized projection platform by photogrammetry vs 3D printed models of various aortic valvular and perivalvular structures will be evaluated the accuracy of each step of image dataset processing. Furthermore, the study will evaluate the rate of valvular leak or peri-procedural complications such as embolic events or atrio-ventricular conduction block based on coronary computed tomography angiographic and ECG assessment at 1 year after enrollment.